Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are ...

They’re non-invasive with none of the dreaded prep. But are recently approved home tests for colon cancer as effective as ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael ...

Reports preliminary FY24 revenue $2.76B, consensus $2.74B. Plans to launch three new cancer tests in 2025, namely Cologuard Plus, ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CDDzvsGh.js ...

Well-known golf writer Steve DiMeglio dies after two-year cancer battle in which he fought to inspire others to have medical ...

3. In July, the FDA approved a new screening test for CRC that only requires a sample of blood. The test, created by Palo Alto, Calif.-based Guardant Health, was able to detect 83% of colorectal ...

A colorectal cancer doctor is making the case for butting into your family’s business. Dr. Parul Shukla, a colon and rectal ...

women are getting colorectal cancer more than men.” If you’re really squeamish about getting a colonoscopy, there are other ways to screen, including a stool test or a Cologuard.

Researchers have developed tests to predict who might benefit from having chemotherapy. Prosigna is one of these tests. The Prosigna test uses a specialist machine to look at a sample of cancer tissue ...

About Exact Sciences Corporation, Gilead Sciences and Inc. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company ...